 PETACH TIKVA, Israel, Jan. 26, 2022 GLOBE NEWSWIRE -- PolyPid Ltd. Nasdaq: PYPD PolyPid or the Company, a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. 